On Tuesday, Lyell Immunopharma Inc (NASDAQ: LYEL) was unchanged from the session before settling in for the closing price of $1.11. A 52-week range for LYEL has been $0.85 – $3.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 428.28%. When this article was written, the company’s average yearly earnings per share was at 14.52%. With a float of $125.06 million, this company’s outstanding shares have now reached $253.96 million.
Let’s determine the extent of company efficiency that accounts for 224 employees. In terms of profitability, gross margin is -23680.95%, operating margin of -348844.44%, and the pretax margin is -323792.06%.
Lyell Immunopharma Inc (LYEL) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lyell Immunopharma Inc stocks. The insider ownership of Lyell Immunopharma Inc is 55.21%, while institutional ownership is 22.60%.
Lyell Immunopharma Inc (LYEL) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.17 earnings per share (EPS) during the time that was better than consensus figure (set at -0.2) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.90% during the next five years compared to -15.28% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
You can see what Lyell Immunopharma Inc (LYEL) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 13.43. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5165.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Looking closely at Lyell Immunopharma Inc (NASDAQ: LYEL), its last 5-days average volume was 0.95 million, which is a drop from its year-to-date volume of 1.0 million. As of the previous 9 days, the stock’s Stochastic %D was 10.79%. Additionally, its Average True Range was 0.12.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 24.30%, which indicates a significant decrease from 40.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 147.38% in the past 14 days, which was higher than the 105.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2061, while its 200-day Moving Average is $1.8358. However, in the short run, Lyell Immunopharma Inc’s stock first resistance to watch stands at $1.1333. Second resistance stands at $1.1567. The third major resistance level sits at $1.1933. If the price goes on to break the first support level at $1.0733, it is likely to go to the next support level at $1.0367. Should the price break the second support level, the third support level stands at $1.0133.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
There are 279,221K outstanding shares of the company, which has a market capitalization of 309.93 million. As of now, sales total 130 K while income totals -234,630 K. Its latest quarter income was 30 K while its last quarter net income were -44,580 K.
